DAS Environmental Experts - German Green Technology from DAS Environmental Experts for Swiss DSM Nutritional Products AG
Moving Bed Biofilm Reactor for sustainable wastewater treatment for the food industry
Dresden/Germany, 29 March 2021. Increasing production capacities have stretched the existing wastewater treatment plant at the chemical company DSM Nutritional Products in Switzerland to its limits. Wastewater characteristics of the chemical industry with strict regulations of the beverage and food industry - the experts of German green technology experts of DAS Environmental Expert GmbH (DAS EE) mastered the challenge and installed a two-stage MBBR plant.
At the site DSM operates the world's largest production facility for vitamin E. The plant also produces pharmaceuticals, substances for the cosmetics industry, dietary supplements and additives such as vitamins, carotenoids and folic acid. The expertise of the Dresden-based environmental technologists was required to handle not only the increased volume, but also the purification of the wastewater. “The wastewater characteristics correspond to those of the chemical industry - but the regulations to be met are similar to those for the beverage and food industries. These strict limits must be reliably met even after the production expansion”, reports Karl Ruediger, project manager at DAS EE.
Initially, a temporary addition to the existing wastewater treatment plant was planned, because the production expansion at the site was accompanied by an increase of the hydraulic load. DAS EE opted for a two-stage MBBR plant (Moving Bed Biofilm Reactor) in order to quickly adapt the wastewater treatment to the planned increase in production.Today, the plant is used under production conditions in the food industry. DAS EE supports DSM with supervision. Online remote maintenance ensures a continuous cost-saving service.
Full report and visuals: http://bit.ly/DAS_EE_DSM
Contact: WeichertMehner (Press), Robert Weichert,
Om news aktuell GmbH
As wholly owned subsidiary of dpa, news aktuell provides business and organizations with effective access to media and consumers. Via the smart tools ots and zimpel, PR content accesses all media formats, including classical print, high click-rate online portals and social networks. In addition, news aktuell publishes all its customers’ PR content on www.presseportal.de, one of the PR portals with the greatest reach in Germany. By this means, all the relevant multipliers are reached globally, from editors, via digital influencers right up to specialist bloggers and interested consumers. news aktuell has been on the market since 1989. The company, with a staff complement of more than 135, has its headquarters in Hamburg. Other offices are in Berlin, Dusseldorf, Frankfurt und Munich.
Følg saker fra news aktuell GmbH
Registrer deg med din epostadresse under for å få de nyeste sakene fra news aktuell GmbH på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra news aktuell GmbH
Grünenthal Group: Grünenthal acquires Mestex AG and its Phase-III-ready investigational medicine MTX-071 for the treatment of pain associated with osteoarthritis of the knee12.4.2021 11:47:13 CEST | Press release
With the acquisition of Mestex AG, Grünenthal secures global rights for an attractive late-stage asset that could offer an innovative therapy option for millions of patients affected by pain related to osteoarthritis of the knee. MTX-071 (resiniferatoxin) is a highly potent Transient Receptor Potential Vanilloid 1 (TRPV1) agonist. Its administration can reversibly defunctionalise TRPV1-expressing nociceptors. This can result in long lasting pain relief. (Aachen, Germany) –Today, Grünenthal has announced the acquisition of Mestex AG through the takeover of all of its shares and options. Mestex AG is a Swiss biotech company that has developed the innovative investigational medicine MTX-071 (resiniferatoxin) for the intra-articular treatment of pain associated with osteoarthritis of the knee. The investigational medicine is currently concluding Phase II of clinical development and is about to enter Phase III. Initial data showed a long-lasting and significant analgesic effect and function
Fluxergy, Inc. Receives CE-IVD Marking for a One-Hour COVID-19 RT-PCR Test and Positions for European Market Entry12.4.2021 09:00:00 CEST | Press release
IRVINE, CA., April 12, 2021 – Fluxergy, Inc., a medical diagnostic testing platform company with a detection technology solution capable of multimodality, announced today that it has obtained CE marking for its one-hour COVID-19 RT-PCR test, to use by healthcare professionals as an in vitro diagnostic (IVD) for the detection of SARS-CoV-2. The CE-mark will allow Fluxergy’s innovative testing platform to enter the European Union market and any other markets that accept CE-marking as valid regulatory approval. Fluxergy’s platform is an automated, sample-to-answer testing platform with multimodal capability allowing for a variety of assay types, such as molecular, immunochemistry, chemistry, and cytometry assays, to be run simultaneously on the same cartridge. This will give users the ability to run unique Point-of-Care (PoC) panels with the potential ability to do built-in reflex testing, among other capabilities. Potential environments for rapid testing applications include emergency ro
Avonisys AG: Avonisys AG wins patent litigation case against Synova SA7.4.2021 15:36:04 CEST | Press release
Swiss Federal Patent Court rules in favour of Avonisys AG in all relevant aspects and convicts Synova SA under the unfair competition act:
Grunenthal Group: Grünenthal is Recognized for its Strong Management of Environmental, Social and Governance (ESG) Risks7.4.2021 11:39:12 CEST | Press release
• Leading global ESG ratings agency Sustainalytics notes Grünenthal is in the top five percent among its peers in the pharmaceutical subindustry • Grünenthal is categorized as “medium risk”, placing it ahead of its key subindustry peers and in the same league as multinational companies like Pfizer and Roche (Aachen, Germany): Grünenthal, a global science-based pharmaceutical company, today announced that Sustainalytics, a Morningstar company and a globally-recognized provider of ESG research, ratings and data, has assessed it as having overall medium ESG risk. In addition, Sustainalytics acknowledged that Grünenthal has a strong management of its ESG risks. This places Grünenthal in the top five percent of the global pharmaceuticals subsector. “The long-term success of companies can no longer be measured by financial success alone. As a science-based company, Grünenthal strives to make a net-positive impact on the society,” said Gabriel Baertschi, CEO Grünenthal. “While we are proud to
Path2Integrity: MORE THAN 200 STUDENTS FROM ACROSS EUROPE TACKLE FAKE NEWS7.4.2021 09:54:12 CEST | Press release
A Europe-wide workshop on Fake News with Rainer Wieland, Vice-President of the European Parliament aims to identify reliable information and encourage responsible action.
DocMorris: Introducing DocMorris Adipositas Care (Obesity Care), a digital hub empowering people with obesity to find relevant care for a better quality of life6.4.2021 09:15:56 CEST | Press release
The Novo Nordisk and Zur Rose Group collaboration presents DocMorris Adipositas Care, a digital hub which provides people living with obesity a new way to find the right care. Adipositas Care thoughtfully empowers people living with obesity by enabling them to learn about obesity and discover possible care solutions, to link to specialized advisors, doctors and digital solutions in obesity care, and by supporting them with the testimonials of peers who took action to better manage their health, all within one digital location. The program launches today in Germany with the intention to expand across other European markets.
MTIP AG: MTIP Announces Strong First Closing of Fund II to drive Healthtech Innovation 1.4.2021 09:00:00 CEST | Press release
MTIP AG, a Basel-based private equity firm that invests in healthtech companies, is pleased to announce that it has completed the first closing of its Fund II. The growth capital fund secured EUR 130m and is well on track towards the target fund size of EUR 200m.
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom